Chair: James Brugarolas, M.D., Ph.D., Associate Professor at the University of Texas Southwestern Medical Center in the departments of Internal Medicine and Developmental Biology, Dallas TX.
M.D., University of Navarra, Spain (1993) Ph.D., Massachusetts Institute of Technology, Cambridge, MA (1998) Internship & Residency in Internal Medicine: Duke University Center, Durham, NC (2001)
Fellowship in Medical Oncology: Dana-Farber Cancer Institute, Boston, MA (2003)
Dr. Brugarolas is the leader of the Kidney Cancer Program and co-leads the Cell Networks Scientific Program of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.
Molecular genetics and biology of renal cell carcinoma
Christopher L. Corless, M.D., Ph.D., Professor in Pathology at the Oregon Health & Science University (OHSU) and Chief Medical Officer for Knight Diagnostic Laboratories at OHSU, Portland, OR.
M.D., Washington University School of Medicine, St. Louis, MO (1988)
Ph.D., Washington University School of Medicine, St. Louis, MO (1988)
Residency in Anatomic Pathology: Brigham and Women's Hospital, Boston, MA (1988-1990)
Fellowship in Gastrointestinal Pathology at Brigham and Women's Hospital, Boston, MA (1990-1992) and in Urologic Pathology at Brigham and Women’s Hospital, Boston, MA (1992-1993)
Molecular Pathology Applications
Zhijian Chen, Ph.D., George L. MacGregor Distinguished Chair in Biomedical Science, Professor in Molecular Biology at the University of Texas Southwestern Medical Center, Dallas, TX; Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD.
Ph.D., State University of New York, Buffalo, NY
Ubiquitin, NF-κB pathway and antiviral signaling
Gordon Freeman, Ph.D., Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Ph.D., Harvard University, Cambridge, MA (1979)
Fellowship in Molecular Immunology, Dana-Farber Cancer Institute, Boston, MA (1979-1984, 1985-1991)
Dr. Freeman’s research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).Research Interests
Jun Qin, Ph.D. Professor in Biochemistry and Molecular Biology, and Molecular and Cellular Biology at the Baylor College of Medicine, Houston, TX.
Ph.D., The Rockefeller University, New York, NY (1996)
Mass spectrometry-based proteomic network analysis
David L. Rimm, M.D., Ph.D. Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology at the Yale University of Medicine.
M.D., John Hopkins University (1989)
Ph.D., John Hopkins University (1989)
Residency in Pathology: Yale-New Haven Hospital, New Haven, CT (1993)
Fellowship in Cytopathology: Medical College of Virginia, Richmond, MA (1994)
Dr. Rimm’s lab group focuses on quantitative pathology using the AQUA® technology, which was invented in his lab, with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer.
Pathology, cytopathology, breast cancer, melanoma, lung cancer, and molecular oncology and diagnostics
David Tuveson, M.D., Ph.D., Professor and Deputy Director of the Cancer Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Also, Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; and Director of Research for the Lustgarten Foundation.
M.D., John Hopkins University, Baltimore, MD
Ph.D., John Hopkins University, Baltimore, MD (1994)
Residency: Brigham and Women’s Hospital, Boston, MA (1994-1997)
Fellowship in Medical Oncology Dana-Farber/Partners Cancer Care, Boston, MA (1997-2000)
Genetics, diagnostics and experimental therapeutics of pancreatic cancer
Thomas Westbrook, Ph.D., Associate Professor in the departments of Biochemistry & Molecular Biology, and Molecular & Human Genetics at Baylor College of Medicine, Houston, TX.
Ph.D., University of Rochester School of Medicine, Rochester, NY (2003)
Postdoctoral fellow, Harvard Medical School, Boston, MA (2003-2007)
Dr. Westbrook leads a research team in breast cancer genetics and genomics and is an American Cancer Society Scholar and a DOD Era of Hope Scholar in breast cancer research.
RNA interference technologies, cancer genes and networks, and cancer therapies
Hongtao Yu, Ph.D., Professor of Pharmacology at University of Texas Southwestern Medical Center, Dallas, TX; Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD.
Ph.D. in Chemistry, Harvard University, Cambridge, MA (1995)
Postdoc in Cell Biology, Harvard Medical School, Boston, MA (1995-1999)
Chromosome Segregation; Mitosis; Histone Modifications; DNA Repair; Protein Structure